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Introduction
Primary systemic vasculitis is characterised by inflam-
mation and necrosis of blood vessel walls. The disease is 
broadly classified according to the size of the vessels 
involved, as proposed by the Chapel Hill Consensus 
Conference [1]. Further categorisation relies on clinical 
and histological findings, as well as the detection of auto-
antibodies. Three of the small vessel vasculitides – 
Wegener’s Granulomatosis (WG), microscopic poly-
angiitis (MPA) and Churg–Strauss syndrome (CSS) – are 
typified by vasculitic lesions with little or no immune 
complex deposition and by anti-neutrophil cytoplasmic 
antibodies (ANCA). These diseases are collectively 
known as ANCA-associated systemic vasculitis (AAV).
Many clinical features are common to all types of AAV, 
includ  ing nonspecific inflammatory symptoms such as 
malaise, fever, anaemia and weight loss. Multiple organ 
systems may be affected; for example, vasculitic lesions 
may manifest as a rash, arthralgia, pulmonary haemor-
rhage and necrotising glomerulonephritis. There are, 
however, phenotypic differences between types of AAV: 
WG characteristically has ear, nose and throat and/or 
respiratory involvement. Necrotising granulomas may 
cause sinusitis, nasal discharge, damage to the nasal 
septum, hearing loss and/or haemoptysis. CSS is asso-
ciated with asthma and eosinophilia. MPA commonly 
affects the kidney without evidence of granulo  mas, upper 
respiratory tract involvement or asthma.
The association with ANCA also varies: 80 to 90% of 
individuals with WG and MPA are ANCA-positive, 
compared with 40% of patients with CSS. The sensitivity 
for ANCA in the diagnosis of WG and MPA is 81 to 85%, 
whilst the specificity (if assayed by both immuno  flour  es-
cence and ELISA) is 98% [2]. The type of ANCA varies with 
AAV subtype; MPA is predominantly associated with 
perinuclear ANCA (p-ANCA) antibodies to the enzyme 
myelo  peroxidase (MPO), whilst patients with WG are more 
likely to have cytoplasmic ANCA (c-ANCA) anti  bodies to 
proteinase 3 (PR3) [3]. Nonetheless, there is consi  der  able 
overlap between the classification of WG and MPA [3,4].
AAV has a substantial morbidity and mortality; 15% of 
patients are dead within 1 year of diagnosis, and 35% are 
dead within 5 years [4]. Although 1-year survival rates 
are similar for all types of AAV (82.7 to 85.5%), survival at 
5 years is worse in patients with MPA (45.1%) compared 
with WG and CSS (75.9% and 68.1%, respectively) [4].
The cause of AAV is not clear, although both environ-
mental factors and genetic susceptibility have been impli-
cated. A number of genetic polymorphisms have been 
associated with AAV, and with WG in particular. This 
suggests that the genetic contribution to AAV is poly-
genic, as with other autoimmune diseases such as rheuma-
toid arthritis, systemic lupus erythematosus (SLE) and 
type 1 diabetes. In these diseases, genetic susceptibility is 
determined by relatively common variants that are found 
throughout the population, each of which contributes 
only modestly to disease risk. This has been termed the 
common disease, common variant hypothesis [5].
Epidemiology
The incidence of AAV across different populations is 
broadly similar at 12 to 18 per million of population per 
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year. The type of vasculitis varies, however, with WG 
being more common in populations from Norway and 
the UK, and MPA more common in Spain and Japan 
[6,7]. The prevalence of WG in a predominantly Northern 
European Caucasian population from New Zealand was 
similar to that in the UK and Norway [8]. These 
population differences in the predominant type of AAV 
may reflect genetic differences and/or environmental 
factors.
Ethnic differences may influence both the type and 
incidence of AAV. Assessment of disease by ethnic distri-
butions in US cohorts suggested WG is more prevalent in 
Caucasians than in African Americans [9]. In New 
Zealand in 2003, the 5-year incidence of WG was twice 
as high in individuals of European ancestry as in those of 
New Zealand Maori or Asian background, whereas 
Pacific Islanders had a rate approximately one-half that of 
New Zealand Maori or Asian [8]. Ethnicity may also be a 
risk factor for all types of AAV when environmental 
factors are controlled – in a French multi-ethnic 
population, AAV was twice as common in individuals of 
European, compared with non-European, ancestry [10], 
suggesting different degrees of genetic risk.
Genetics
More direct evidence for a genetic basis for WG comes 
from a recent familial aggregation study. This found a 
relative risk of 1.56 for first-degree relatives of patients 
with WG [11], which is similar to that seen in rheumatoid 
arthritis [12,13] and suggests there are genetic risk factors 
for WG. In addition, case reports of familial clustering in 
AAV have reported polyarteritis nodosa and CSS 
occurring amongst relatives of patients with WG [14,15], 
suggesting common genetic risk factors may predispose 
to different types of vasculitis.
A number of candidate gene association studies have 
identified variants associated with an increased incidence 
of AAV. Most of the genes so far described encode 
proteins involved in the immune response (Table 1).
Replicated genetic associations
Major histocompatibility complex
The human MHC region spans 3.6 Mb containing more 
than 250 genes, more than one-half of which have 
immuno  logical functions. Variants in MHC have been 
strongly associated with several autoimmune diseases, 
including type 1 diabetes [16] and SLE [17]. A number of 
small studies have suggested associations between WG 
and MHC loci, including HLA-B50 [18], HLA-DQw7 
[19], HLA-DR3 [19], HLA-DR1 [20] and HLA-DR9 [18].
More significantly, a recent study revealed a strong 
asso  ciation of WG with an allele encoding class II 
molecule DPB1*0401 (odds ratio (OR) = 3.91, P = 1.51 x 
10–10). In addition, the extended haplotype DPB1*0401/
RXRB03 showed an even stronger association with WG 
(OR = 6.41, P = 7.13 x 10–17) [21], raising the possibility of 
additional susceptibility loci. A more recent study has 
replicated the association of the DPB1*0401 allele with 
WG. A single nucleotide polymorphism (SNP) 3΄ of 
HLA-DPB1 was most associated (P = 6.4 x 10–8), whilst 
another SNP in the vicinity of RING1 (which encodes a 
transcriptional repressor) also showed a significant WG 
association that was partly independent of the HLA-
DPB1 effect [22]. The HLA-DR4 allele was also associated 
with susceptibility to both AAV (in general) and WG (in a 
subset) in a study of 304 Dutch patients and 9,872 
controls [23]. Between the four disease subsets (WG, 
MPA, CSS and renal-limited vasculitis), the HLA antigen 
distribution did not differ – except for DR8, which was 
more prevalent in patients with CSS than in the other 
three groups of AAV (P <0.0001) [23].
Two studies have identified an association between 
susceptibility to CSS and HLA-DRB4, whilst HLA-DRB3 
was associated with protection against the disease 
[24,25]. As WG and CSS are thus associated with differ-
ent HLA genotypes, it has been argued that they may in 
fact be separate disease entities, and not closely related 
disease variants as previously thought [24].
PRTN3 gene
The genes encoding ANCA target antigens may play a 
role in the pathogenesis of AAV. PRTN3 encodes PR3, an 
intracellular serum protease against which ANCA are 
commonly directed in WG. PR3 is also expressed on the 
surface expression of neutrophils. The expression pattern 
is bimodal in individuals; the proportion of neutrophils 
that are high or low expressers remains constant over 
time, and is unaffected by age or gender [26]. This surface 
expression pattern correlates much more closely in 
monozygotic twins (r = 0.99) than dizygotic twins 
(r = 0.06), suggesting it is genetically determined [27]. 
One study found that the distribution of membrane-
bound PR3 in 37 AAV patients (16 with WG, 21 with 
MPA) was significantly skewed toward the membrane-
bound PR3 high phenotype when compared with 126 
healthy controls; 85% of AAV patients expressed high 
levels of membrane-bound PR3 versus 55% in healthy 
subjects [26]. This finding was replicated in a second 
study, which also showed that in 89 WG patients an 
elevated level of membrane-bound PR3 expression was 
significantly associated with an increased relapse rate 
(P = 0.011), but not with the disease extent or particular 
manifestations at diagnosis [28]. Interestingly, a study in 
17 sibling pairs matched at 34 HLA antigens showed a 
high concordance in neutrophil membrane-bound PR3 
expression (r = 0.67, P <0.05), approaching that seen in 
monozygotic twins [29]. The authors propose that the 
percentage of membrane  PR3-positive neutrophils is 
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Table 1. Positive genetic association studies in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis
Gene  Population origin  Cases  Controls  Odds ratio  P value  Reference
HLA DPB1*0401  Germany  150 WG  100  3.9  1.5 x 10–10 [21]
HLA DPB1*0401  Germany  282 WG  380    6.4 x 10–8  [22]
HLA B50  North America,   83 WG  4,039  4.89a <0.0001  [18]
 Caucasian
HLA DR9  North America,   76 WG  4,039  4.00a 0.005  [18]
 Caucasian
HLA DQw7  UK  34 WG, 25 MPA  1,103  2.9  <0.0025  [19]
HLA DR3  UK  34 WG, 25 MPA  1,103  0.31  <0.01  [19]
HLA DR1  UK  27 WG  500 to 2,000?  2.3  0.0001  [20]
HLA DR4  The Netherlands  304 (241 WG, 30 MPA, 12 CSS, 21 RLV)  9,872  1.7  <0.0001  [23]
HLA DR6  The Netherlands  304 (241 WG, 30 MPA, 12 CSS, 21 RLV)  9,872  0.3  <0.0001  [23]
HLA DRB4  Italy  48 CSS  350  2.49  2.3 x 10–4 [25]
HLA DRB3 Italy  48  CSS  350  0.54  0.028  [25]
HLA DRB4  Germany  102 CSS  341  1.87  2 x 10–4 [24]
HLA DRB3 Germany  102  CSS  341  0.61  0.004  [24]
          
PTPN22-620W Germany  199  WG  399  1.8  0.002  [41]
PTPN22-620W  UK  641 (WG, MPA and CSS)  9,115  1.4  1.4 x 10–4  [43]
IL-2RA rs41295061  UK  675 (WG, MPA and CSS)  8,936  0.77  0.012  [42]
CTLA4 –318T Sweden  32  WG  122  3.26 <0.05  [46]
CTLA4 +49G  The Netherlands  50 WG, 24 MPA, 7 CSS, 21 RLV  188  1.32  0.01  [48]
CTLA4 rs3087243  UK  641 (WG, MPA and CSS)  9,115  1.19  6.4 x 10–3 [43]
PRTN3 –564G Germany  66  WG  106  0.5  <0.01  [30]
AAT Z allele  Italy  33 WG, 28 MPA, 23 RLV   200  3.7a 0.022  [36]
AAT Z allele  Austria  29 WG, 2 MPA, 1 RLV  868  13.2  <0.0001  [37]
AAT Z allele Germany 79  WG  752 3.8a <0.0001  [35]
 AAT Z allele Sweden  88  (66  WG)  ?  6.0 <0.0001  [95]
AAT Z allele Scandinavia  44  WG  ?  ?  <0.001  [34]
C3F  Sweden  34 WG, 33 MPA  101  0.52  <0.05  [58]
CD18 Ava II   Germany  31 MPO positive  120  2.56  <0.005  [57]
IL-10 microsatellite Sweden  32  WG  109  7.94  <0.0032  [51]
IL-10 (–1082)   Germany  125 WG, 36 MPA  153  0.30  <0.0001  [52]
AA genotype
IL-10 haplotype Germany  103  CSS  507  2.16  0.0003  [53]
LILRA2 intron 6   Japan  50 MPA  284  2.52  0.049  [54]
AA genotype
CD226 rs763361 Germany  642  WG  1226  1.20  0.016  [56]
FCGR2A R131   The Netherlands  91 WG  154  4.60  0.0092  [64]
RR genotype
with FCGR3A F158 FF
          
FCGR3B copy   UK  556 (WG, MPA and CSS)  286    1 x 10–8 [74]
number high
FCGR3B copy   UK  80 WG  190    0.003  [73]
number low
FCGR3B copy   UK  76 MPA  190    0.0003  [73]
number low
FCGR3B copy   France  84 WG  181    0.0001  [73]
number low
CSS, Churg–Strauss syndrome; MPA, microscopic polyangiitis; MPO, myeloperoxidase; RLV = renal-limited vasculitis; WG, Wegener’s granulomatosis. aNo odds ratio 
given in the reference; values calculated using Graphpad prism, 2 x 2 chi-squared test.
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dictated by HLA  antigens, but do not suggest a 
mechanism for this effect.
Eight SNPs have been identified in the promoter and 
exonic sequences of PRTN3, and a polymorphism in the 
promoter region of PRTN3 (A-564G), affecting a putative 
transcription factor binding site, was associated with WG 
when allele frequencies were compared in 66 cases and 
106 controls [30]. This study also identified a strong 
association between a haplotype of two of these eight 
SNPs and WG (P <10–5). It has not yet been shown 
whether these polymorphisms affect PR3 expression.
Expression of membrane PR3 on neutrophils is 
therefore likely to be genetically determined, and 
individuals with high levels of expression are at increased 
risk of AAV. The genetic polymorphisms that cause this 
variation in expression have not been fully elucidated.
α1-Antitrypsin
PR3 is released when activated neutrophils degranulate, 
and directly damages endothelial cells – in vitro, the 
enzyme causes detachment and cytolysis of endothelial 
cells. The cationic enzyme also binds covalently to the 
endothelium, where it can bind ANCA and thus trigger 
antibody-dependent cytotoxicity [31]. α1-Antitrypsin is 
the major inhibitor of PR3 activity, and is thought to limit 
the damage done to local tissues. The gene encoding 
α1-antitrypsin (AAT) is highly polymorphic, and several 
of the polymorphisms, including the Z and S alleles, 
reduce the function of the protein. The decreased 
function of α1-antitrypsin may result in persistence of 
PR3 in inflammatory tissue for longer, which may in turn 
result in the generation of ANCA.
Several groups have found an association of the presence 
of Z and S alleles with cANCA-positive and pANCA-
positive vasculitis, respectively [32], anti-PR3 antibodies 
[33], WG [34,35] or all AAV [36,37]. Neither anti-PR3 
antibodies nor clinical features of WG were detected in 
191 α1-antitrypsin Z homozygotes [38], indicating that 
the deficiency contributes to, but is not the sole genetic 
determinant of, risk of AAV.
PTPN22 gene
PTPN22  encodes protein tyrosine phosphatase non-
receptor type 22, an enzyme expressed predominantly by 
lymphocytes. The 620W (rs2476601) allelic variant of 
PTPN22 is associated with several autoimmune 
disorders, including type 1 diabetes mellitus, SLE and 
rheumatoid arthritis [39]. The associated allele appears 
to influence thres  holds for T-cell receptor signalling, but 
the precise mechanisms for these associations remain 
unclear. In general, the PTPN22 620W allele has been 
implicated in autoimmune disorders that have a 
prominent humoral component, suggesting that PTPN22 
activity in B cells may be important [40].
A study of 199 WG patients found an increase in the 
PTPN22 620W allele with an OR of 1.75 (95% confidence 
interval (CI) = 1.21 to 2.48, P = 0.002) [41]. We genotyped 
this SNP in 641 AAV cases derived from four UK sources, 
including 205 patients with WG and 74 patients with 
MPA (further details of these sample collections are given 
in [42]). We found an association of all AAV with the 
minor allele (P = 1 x 10–4, OR = 1.4; 95% CI 1.18 to 1.67), 
as well as an association with both WG and MPA when a 
subset of these patients with these diagnoses were 
analysed independently (WG, P = 6.0 x 10–11, OR = 2.0; 
MPA, P = 4.1 x 10–6, OR = 2.55) [43]. Thus, this SNP is 
likely to contribute to the risk of AAV, as well as other 
autoantibody-associated autoimmune diseases.
Cytotoxic T-lymphocyte antigen 4
CTLA4 (cytotoxic T-lymphocyte antigen 4) is mainly 
expressed on CD4+ T cells. When bound to its ligands 
(CD80 and CD86 on B cells and dendritic cells), CTLA4 
inhibits T-cell function. Increased expression of CTLA4 
is seen in WG [44]. Polymorphisms in CTLA4 have been 
associated with a number of autoimmune diseases [45]. 
Heterozygosity for a SNP in the promoter region of 
CTLA4 has been linked to WG [46], and this SNP has 
been shown to affect protein expression [47]. A small 
study of CTLA4 SNPs did not find a significant 
association with this promoter polymorphism in a study 
of 102 patients and 188 controls, but found that a 
different SNP (+49G) was associated with AAV when 
individuals either heterozygote or homozygote for the G 
allele were compared [48]. We found an association of 
another autoimmune disease-associated SNP in CTLA4 
(rs3087243) with AAV in the 641 cases and 9,115 controls 
described above (P = 6.4 x 10–3, OR = 1.19; 95% CI = 1.05 
to 1.34) [43]. The association of CTLA polymorphisms 
with other autoimmune diseases strengthens the case 
that SNPs in this gene to contribute to AAV susceptibility.
Unreplicated associations
High-affi   nity IL-2 receptor
The cytokine IL-2 drives the division and survival of 
effector T cells, and is also important in regulatory T-cell 
homeostasis. Activated T cells and regulatory T  cells 
express the high-affinity IL-2 receptor (IL-2RA or CD25). 
The receptor is also expressed on other immune cells 
including activated B cells, dendritic cells and activated 
monocytes, where its physiological role is less well 
defined. Polymorphisms in the IL-2RA locus have been 
associated with type 1 diabetes, multiple sclerosis and 
Graves’ disease [49]. When rs41295061, one of the SNPs 
associated with type 1 diabetes, was compared in 744 
AAV cases (comprising WG, MPA and CSS) and 9,115 
controls, the minor allele frequency was increased in 
AAV cases (P = 0.012, OR = 0.77; 95% CI = 0.63 to 0.95) 
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[42]. Furthermore, soluble IL-2RA concentrations in the 
serum of AAV patients were higher than in controls, and 
disease activity as assessed by the Birmingham Vasculitis 
Activity Score also showed a positive correlation with 
soluble IL-2RA concentrations [42], as has pre  viously 
been reported in WG patients [50]. The differ  ences in 
soluble IL-2RA provide a physiological correlate of 
genetic variation that may contribute to the AAV risk.
Interleukin-10
IL-10 is an anti-inflammatory cytokine produced 
primarily by monocytes and to a lesser extent by 
lymphocytes. This cytokine has pleiotropic effects on 
immunoregulation and inflammation. It downregulates 
the expression of Th1 cytokines, MHC class II antigens, 
and co-stimulatory molecules on macrophages. It also 
enhances B-cell survival, proliferation, and antibody 
production. A small study of 32 WG patients found an 
association with a polymorphism in IL-10  that has 
previously been associated with autoantibody production 
[51]. A larger study of 125 WG cases and 153 controls 
also found a SNP in IL-10 was associated with WG [52], 
with homozygosity for the minor allele over-represented 
in the patients (P = 0.0021; OR = 0.354; 95% CI = 0.183–
0.684). Conversely, a study of 403 WG patients did not 
find an association with three SNPs in IL-10, although a 
haplotype was associated with ANCA-negative CSS [53]. 
Further studies are needed to clarify the role of poly-
morphisms in the gene encoding this anti-inflammatory 
cytokine.
Leukocyte immunoglobulin-like receptor A2
LILRA2 is one member of the family of leukocyte 
immunoglobulin-like receptors. The leukocyte immuno-
globulin-like receptors in subfamily A initiate stimulatory 
cascades, and LILRA2 is involved in the activation of 
granulocytes and macrophages. A SNP in LILRA2 
(rs2241524 G>A) activates a cryptic splice acceptor site, 
resulting in a novel LILRA2 isoform. Homozygosity for 
the minor allele of SNP was associated with both SLE and 
MPA in a recent study [54], although only 50 MPA 
patients were included.
CD226 gene
CD226 (DNAX accessory molecule 1) is an immuno-
globulin superfamily adhesion molecule expressed on the 
surface of natural killer cells, platelets, monocytes and 
T cells. It binds CD155, which is found on epithelial cells, 
endothelial cells and antigen-presenting cells. CD226 
appears to contribute to multiple innate and adaptive 
responses, including leukocyte migration, activation and 
expansion differentiation of CD8 T cells and CD4 T cells, 
and effector responses of T cells and natural killer cells 
[55]. The minor allele of a polymorphism in CD226, 
rs763361, which encodes a glycine to serine substitution 
at position 307, was associated with disease in two 
German WG cohorts (OR = 1.23, P = 0.0031), but not in 
a UK cohort [56]. When we studied this polymorphism 
in 641 UK cases and 9,115 controls, we did not find an 
association with AAV, or with WG in a subset analysis 
[43]. This suggests that the disease risk associated with 
the minor allele of this polymorphism is much smaller in 
UK Caucasians than in German Caucasians.
Associations with other single nucleotide polymorphisms
A SNP in the gene encoding integrin CD18, a leucocyte 
adhesion molecule, has been associated with MPO 
ANCA-positive AAV [57], and another in the gene for 
complement component C3 has been associated with a 
combination of WG and MPA [58]. These studies are too 
small to be conclusive without replication.
Several groups have looked for an association between 
AAV and polymorphisms in TNF genes (encoding the 
proinflammatory cytokines TNFα and TNFβ), and none 
have shown statistically significant differences [59,60].
Fcγ receptors
The low-affinity Fcγ receptors (FcγRs) bind the Fc 
portion of IgG and mediate the effects of IgG immune 
complexes on leucocytes, resulting in immune responses 
that include recruitment to inflammatory lesions, phago-
cytosis, antibody-dependent cellular cytotoxicity, release 
of inflammatory mediators and antibody production. The 
activation of primed neutrophils by ANCA requires 
FcγRs. Human neutrophils constitutively express the 
low-affinity activatory FcγRs, FcγRIIa (CD32) and 
FcγRIIIb (CD16), and both of these receptors have been 
shown to play a role in ANCA-induced neutrophil 
activation [61]. ANCA crosslink MPO and PR3 with 
these FcγRs to trigger intracellular signalling, which 
results in superoxide production, proinflammatory cyto-
kine release and degranulation [31]. Both FCGR2A and 
FCGR3B have functionally significant polymorphisms.
Fcγ receptor IIa
FcγRIIa is a low-affinity, activatory FcγR expressed on 
monocytes, macrophages, platelets and activated 
dendritic cells as well as neutrophils. A polymorphism in 
FCGR2A results in a histidine to arginine substitution at 
amino acid position 131, altering receptor affinity and 
specificity for IgG subtypes – FcγRIIa-H/131 binds IgG2 
and IgG3 with increased avidity compared with the 
FcγRIIa-R131 homozygous genotype. In acute AAV, IgG3 
predominates [62] and sera with higher IgG3 ANCA 
levels can preferentially activate neutrophils [63]. The 
FcγRIIa-R131 homozygous genotype, in combina  tion 
with homozygosity for an allelic form of FcγRIIIa, was 
over-represented in Dutch patients with WG, and was 
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also associated with increased disease relapse rates [64]. 
Individuals with the FcγRIIa-R131 homozygous genotype 
have a reduced ability to phagocytose Staphlococcus 
aureus, which provokes an IgG2 antibody response [65]. 
Chronic nasal carriage of S. aureus has been associated 
with higher relapse rates in patients with WG [66], and 
thus the FcγRIIa-R131 homozygous genotype may 
predispose to WG relapse by reducing clearance of the 
bacterium. In a British study, however, no significant 
association was found between FcγRIIa genotype and 
ANCA-positive vasculitis or nephritis in 107 patients and 
100 controls [67], although this study was powered to 
detect a minimum OR of 2.48, and smaller effect sizes 
cannot be excluded.
Fcγ receptor IIIb
FcγRIIIb is a low-affinity, glycosylphosphatidylinositol-
linked FcγR expressed only on human neutrophils. The 
receptor is activatory, and is thought to signal through 
association with complement receptor 3, FcγRIIa, or lipid 
rafts. FcγRIIIb can also be released from the surface of 
neutrophils upon activation. FCGR3B has two poly-
morphic forms, which differ by five nucleotides (141, 147, 
227, 277, and 349) within exon 3, resulting in a four-
amino-acid substitution in its membrane-distal immuno-
globulin-like extracellular domain. This gives rise to two 
isoforms termed FγRIIIb-HNA1a and FcγRIIIb-HNA1b 
(previously known as NA1 and NA2, respectively), which 
have different IgG subtype affinities. FcγRIIIb-HNA1a 
has a higher affinity for IgG3, so might be expected to be 
associated with AAV. ANCA responses are greater in 
neutrophils from FcγRIIIb-HNA1a donors [68], and one 
study has shown a nonsignificant trend to an association 
of FCGR3B HNA1a with AAV [68]. However, FCGR3B 
has recently been shown to be present at variable copy 
number (see below), and these association studies need 
to be reinterpreted in the light of analysis of CNV.
Copy number variation
Copy number variation has been defined as a DNA 
segment that is 1 kb or larger and is present at variable 
copy numbers in comparison with a reference genome. 
As much as 5% of the human genome may lie within copy 
number variable regions [69]. The implications of such 
widespread genetic copy number variation on phenotypic 
variation are as yet uncertain, but some copy number 
variants clearly have a functional effect. For example, the 
copy number of CCL3LI has been associated with 
susceptibility to SLE [70], rheumatoid arthritis [71] and 
type 1 diabetes [71]. SLE has also been associated with 
variable copy number in the genes encoding complement 
component C4 [72], as well as in FCGR3B [73,74]. In vitro 
studies have shown that the FCGR3B copy number 
correlates with protein expression, with neutrophil 
uptake of and adherence to immune complexes, and with 
soluble serum FcγRIIIb [74].
There is controversy regarding the association of 
FCGR3B copy number with AAV: Fanciulli and 
colleagues showed an association with low copy number 
in two WG cohorts of 80 and 84 patients, and in an MPA 
cohort of 76 patients [73]; whilst Willcocks and 
colleagues compared 556 patients with AAV from three 
different cohorts with 286 controls, and found in all three 
cohorts that AAV was associated with high FCGR3B 
copy number [74]. Copy number assays, however, often 
produce results that are continuously distributed across 
the population, rather than falling into discrete bins asso-
ciated with copy numbers [75]. Difficulties in copy 
number assignation may therefore underlie these 
conflicting results. The association of the FCGR3B copy 
number with AAV needs to be reassessed now a more 
reliable copy number assay has been described [76].
Thus, although in vitro data implicate the FcγRs in 
mediating the actions of ANCA on neutrophil activation, 
a definitive view on the contribution of genetic variation 
in the FCGR locus to AAV requires a study which takes 
into account both SNPs, CNV and their potential 
interactions.
Summary of genetic evidence
Many genetic factors have been implicated in the 
pathogenesis of AAV. The increased risk in family 
members with WG is comparable with that seen in 
rheumatoid arthritis, for which genetic risk factors have 
been well characterised. Indeed, the genes with variants 
most strongly associated with AAV, the MHC and 
PTPN22 genes, also have variants associated with other 
autoimmune diseases, including rheumatoid arthritis, 
type 1 diabetes and SLE [39,45]. This suggests that 
genetic risk factors common to other autoimmune 
diseases also apply to AAV. Different variants within each 
gene may be associated with different polymorphisms – 
for example, SLE associates with IL-2RA SNP 
rs11594656, while AAV is associated with rs41295061 
[42]. Table 1 summarises results from positive genetic 
association studies performed to date. Most of these 
studies are either composed solely of patients with WG, 
or include a majority of patients with this type of AAV. It 
is not yet clear whether this is because the genetic 
contribution to WG is greater than that seen in the other 
types of AAV or whether this simply reflects the case mix 
of AAV in Northern European countries, where most of 
these studies have been performed. Larger cohorts need 
to be studied to allow subset analysis of the different 
types of AAV.
Several common autoimmune diseases have been the 
subject of genome-wide association studies, in which 
hundreds of thousands of SNPs throughout the genome 
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are compared in cases and controls. These studies have 
identified new associations with variants in genes not 
previously known to be involved in pathogenesis; for 
example, in inflammatory bowel disease, the genes 
involved in the autophagy pathway [77]. Such associa-
tions identify new approaches for diagnosis and treat-
ment, and a genome-wide study of AAV may be similarly 
enlightening.
Environmental triggers and anti-neutrophil 
cytoplasmic antibody-associated systemic vasculitis
The environmental agents that trigger the onset of AAV in 
genetically susceptible individuals remain elusive in the 
majority of patients. Epidemiological evidence suggests 
that the AAV is more common in people chronically 
exposed to a wide variety of environmental toxins, 
including pesticide, livestock, high solvent exposure, 
asbestos, hydrocarbon fumes and silica (reviewed in [78]). 
Evidence for causality is strongest for silica: exposed 
patients typically have the clinical syndrome of MPA and 
have ANCA that include specificity for MPO rather than 
for PR3 [79]. The mechanisms are unknown but could 
relate to the chronic proinflammatory effects of silica on 
macrophages and the consequent adjuvant effect of 
adaptive immune responses [80].
Drugs
The evidence that therapeutic drugs can induce AAV is 
more convincing. As many as one-half of patients treated 
with the anti-thyroid drug propylthiouracil may develop 
positive ANCA and anti-MPO assays, although far fewer 
develop overt vasculitis [81]. AAV has been reported 
after treatment with hydralazine for hypertension [82] 
and after penicillamine therapy for rheumatic disease 
[83], in both cases with pANCA-associated focal necro-
tising glomerulonephritis.
Infections
As only a small fraction of those presenting with AAV are 
exposed to these chemical triggers, other environmental 
agents must be involved, and these are commonly 
assumed to be infections, a view re-enforced by 
increasing evidence that bacterial infections are the 
initial event that breaks tolerance, resulting in auto-
immunity in other contexts. Attempts to use data on the 
seasonal incidence of AAV to support a role for infection 
have been unhelpful – some studies have suggested that 
the incidence of WG is higher in the winter, when 
infection rates are higher, but other studies have not 
confirmed this suggestion (reviewed in [78]). None  the-
less, nearly two-thirds of patients presenting with WG 
are nasal carriers of S.  aureus  (significantly higher 
incidence than the general population) and nasal 
colonisation with S. aureus greatly increases the risk of 
disease relapse (relative risk 7.2), suggesting direct 
involve  ment [66]. Furthermore, in a randomised con-
trolled trial, prophylactic treatment with co-trimoxazole 
reduced relapse rates by 60% [84]. ANCA positivity has 
been reported in patients with bacterial endocarditis, 
some of whom develop features of vasculitis [85]. In two 
of these, S. aureus was the causative organism [86,87], 
which may again point to a link between this species and 
AAV.
Molecular mimicry between pathogen and host 
proteins is often proposed as an explanation for the 
association between infection and autoimmunity [88]. 
This occurs when exposure to foreign proteins provokes 
synthesis of antibodies that cross-react with host proteins 
due to sequence or structural similarities. The resulting 
autoantibodies then cause disease. In an era of database 
searches, however, it is remarkably simple to find 
sequence homologies over eight to 10 amino acids that 
might be contained in a B-cell epitope. Consequently, 
claims for molecular mimicry need to be judged against 
stringent criteria before they can be accepted [89].
The evidence for S. aureus being a molecular mimic 
does not meet these standards: there are no known 
homologies between S. aureus proteins and the common 
ANCA targets MPO, PR3 and the more recently 
described LAMP-2 [90]; and similarly there are no 
suggestions that ANCA bind directly to S. aureus. No 
homologies have been identified between S. aureus 
proteins and the common ANCA targets, and no evidence 
has been published suggesting that ANCA themselves 
bind to S. aureus proteins.  Accordingly there is no 
evidence that S. aureus is a conventional molecular mimic.
Pendergraft and colleagues suggested a more complex 
form of molecular mimicry to link S. aureus with 
anti-PR3 antibodies [91]. They noted that a proportion of 
patients with AAV and anti-PR3 antibodies also had 
circulating antibodies that recognised the complementary 
PR3 sequence – i.e. the protein that would result from 
transcription of the antisense strand of the PR3 gene.   
When they immunized mice with complementary PR3, 
antibodies developed to both complementary PR3 and 
subsequently to PR3, thus in mice at least, anti-PR3 and 
anti- complementary PR3 antibodies are idiotypes for 
each other [91]. Intriguingly, there is a weak homology 
between complementary PR3 and S. aureus proteins, and 
Pendergraft  et al. suggested exposure to S. aureus 
induced anti-complementary PR3 antibodies that in turn 
induced anti-PR3 antibodies and AAV. However, there is 
no evidence that anti-complementary PR3 antibodies 
cross-react with S. aureus. Furthermore, rodents 
immunised with S. aureus do not develop AAV [92] – 
although, interestingly, immuni  sation with Escherichia coli 
used as a control in this study did induce AAV in a small 
proportion of animals.
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Until recently, attempts to link bacterial infection and 
AAV have been based on the idea that autoantibodies to 
the classical ANCA targets MPO and PR3 are the cause 
of AAV, but this is still the subject of considerable debate. 
These antibodies are closely associated with AAV and its 
activity, and there is compelling evidence that they can 
cause endothelial injury in vitro, and in vivo in the case of 
anti-MPO antibodies (reviewed in [31]). Kain and 
colleagues recently provided evidence that antibodies to 
LAMP-2 may have a pathogenic role in AAV, as well as 
providing evidence of molecular mimicry between 
LAMP-2 and the bacterial adhesion protein FimH [90].
LAMP-2 is a heavily glycosylated type 2 membrane 
protein found in high concentrations in lysosomes that 
also shuttles to the cell surface. Surface LAMP-2 has a 
role in cell adhesion, whilst intracellular LAMP-2 is 
critical for autophagy and presentation of intracellular 
antigens [93]. In neutrophils, LAMP-2 is found in the 
same vesicles as MPO and PR3 – consequently, auto-
antibodies to LAMP-2 give positive results in fluorescent 
ANCA assays. LAMP-2 is also present on the cell 
membrane, however, and is immediately accessible to 
circulating  auto anti bodies  [94].
Kain and colleagues  found that autoantibodies to 
LAMP-2 were present in over 90% of a cohort of 84 
patients with active AAV and pauci-immune focal necro-
tising glomerulonephritis, whereas autoantibodies to 
MPO and PR3 were each found in just under one-half of 
patients [90]. By contrast, assays to anti-LAMP-2 
antibodies were negative when patients were in 
remission. A monoclonal antibody to human LAMP-2 
activated neutrophils in vitro and induced apoptosis of 
human endothelial cells. Rats injected with polyclonal 
anti-LAMP-2 antibodies developed severe pauci-immune 
focal necrotising glomerulonephritis, confirming that the 
antibodies could be pathogenic.
Epitope mapping identified two dominant epitopes 
recognised by patients’ autoantibodies, one of which, 
termed P31.39, was homologous (with eight out of nine 
amino acids identical) to a sequence in the mannose 
Figure 1. Proposed mechanism of action for antibodies to LAMP-2 in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis 
[90]. (a) Antibodies develop to FimH, an antigen found on fi  mbriated bacteria such as E. coli, develop during an infection. (b) In genetically 
susceptible individuals, these antibodies cross react with LAMP2, a widely-expressed protein found on cell surfaces as well as in lysosomes. (c) The 
auto-antibodies bind to LAMP2 on the surface of neutrophils and endothelial cells causing apoptosis. (d) Antibodies to LAMP2 may also mediate 
adherence of neutrophils to endothelial cells via Fcγ receptors. (e) Subsequent neutrophil degranulation causes endothelial cell necrosis and thus 
vasculitis.
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binding pocket of FimH, an adhesin expressed by Gram-
negative bacteria. Patients’ autoantibodies cross-reacted 
with FimH, and rats immunised with FimH developed 
anti-FimH antibodies that cross-reacted with human and 
rat LAMP-2. The immunised rats also developed AAV 
with pauci-immune focal necrotising glomerulonephritis. 
Kain and colleagues hypothesise that molecular mimicry 
between the two proteins causes antibodies to LAMP-2 
in susceptible individuals after infection with fimbriated 
bacteria, and this in turn causes AAV (as illustrated in 
Figure 1). More data will be needed to confirm this novel 
hypothesis.
Conclusion
In summary, we have reviewed evidence that strongly 
supports the existence of genetic risk factors for AAV. As 
with other polygenic autoimmune diseases – for example, 
rheumatoid arthritis and SLE – AAV is likely to result 
from complex interactions between genetic variants and 
environmental triggers. Infection may trigger AAV, and 
we have outlined a number of possible mechanisms for 
this trigger. In particular, we have discussed a recently 
reported example of molecular mimicry which provides a 
new model for the pathogenesis of this autoimmune 
disease [90].
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